PLoS ONE · 2013 · 22 citations · 33 references
Life SciencesInfectious DiseasesMolecular BiologyDrug DesignMolecular VirologyVirologyAntiviral AgentsAntiviral ImmunityAntiviral PharmacologyAntiviral PharmacotherapyAntiviral TherapyPeptide Drug DiscoveryAntiviral Drug DesignAntiviral PeptidesAntiviral TherapeuticsFeline Infectious DiseasesFeline VirusesPlaque ReductionViral Replication InhibitorsViral Spike Proteins
BACKGROUND: Feline infectious peritonitis (FIP) is a lethal immune-mediated disease caused by feline coronavirus (FCoV). Currently, no therapy with proven efficacy is available. In searching for agents that may prove clinically effective against FCoV infection, five analogous overlapping peptides were designed and synthesized based on the putative heptad repeat 2 (HR2) sequence of the spike protein of FCoV, and the antiviral efficacy was evaluated. METHODS: Plaque reduction assay and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cytotoxicity assay were performed in this study. Peptides were selected using a plaque reduction assay to inhibit Feline coronavirus infection. RESULTS: The results demonstrated that peptide (FP5) at concentrations below 20 μM inhibited viral replication by up to 97%. The peptide (FP5) exhibiting the most effective antiviral effect was further combined with a known anti-viral agent, human interferon-α (IFN-α), and a significant synergistic antiviral effect was observed. CONCLUSION: Our data suggest that the synthetic peptide FP5 could serve as a valuable addition to the current FIP prevention methods.
33
Berend‐Jan Bosch, Ruurd van der Zee, Cornelis A. M. de Haan et al. · Journal of Virology · 2003 · 1.6K citations · Full text
Carl Wild, D C Shugars, Teresa Greenwell et al. · Proceedings of the National Academy of Sciences · 1994 · 933 citations · Full text